CriticalSelective If channel inhibitor of the sinoatrial node×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The liver and gut break down ivabradine only through the enzyme CYP3A4, and strong inhibitors of this enzyme raise its levels sharply. Ketoconazole 200 mg once daily and josamycin 1 g twice daily increased mean ivabradine exposure 7- to 8-fold (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). According to its own documents, voriconazole strongly inhibits CYP3A4 (voriconazole SmPC, EMA, and label, US Food and Drug Administration, FDA). No study has tested the pair. According to the voriconazole SmPC and label, higher ivabradine levels can prolong the corrected QT interval (QTc) and, rarely, cause torsade de pointes (voriconazole SmPC, EMA, and label, FDA). High ivabradine levels carry a risk of excessive bradycardia, and a slow heart rate can itself make QT prolongation worse (ivabradine SmPC, EMA). QTc prolongation has also occurred with voriconazole (voriconazole SmPC, EMA).
Symptoms
Excessive bradycardia shows as a resting heart rate persistently below 50 beats per minute, dizziness, fatigue and low blood pressure (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). Sinus arrest and heart block can occur (ivabradine label, US Food and Drug Administration, FDA). Bradycardia together with a prolonged QT interval on the electrocardiogram (ECG) raises the risk of severe ventricular arrhythmia, including torsade de pointes (ivabradine FDA label). Ivabradine overdose causes severe and prolonged bradycardia. Luminous phenomena in the visual field (phosphenes) depend on the dose, as bradycardia does (ivabradine SmPC, EMA).
Management
The combination is contraindicated. The voriconazole documents name ivabradine among the drugs that must not be given with voriconazole. These drugs depend heavily on the enzyme CYP3A4 for their metabolism, and high levels of them are linked to serious or life-threatening reactions (voriconazole summaries of product characteristics, SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS; voriconazole label, US Food and Drug Administration, FDA). The US ivabradine label contraindicates all strong CYP3A4 inhibitors and names azole antifungals among them (ivabradine FDA label). Voriconazole strongly inhibits this enzyme (voriconazole SmPC, EMA, and label, FDA). The European ivabradine SmPC also advises avoiding drugs that prolong the QT interval on the electrocardiogram (ECG) (ivabradine SmPC, EMA). QT prolongation has occurred with voriconazole (voriconazole SmPC, EMA). Pause ivabradine for the whole course of voriconazole, as follows from the contraindication. The documents give no waiting time before restarting ivabradine after voriconazole is stopped. The half-life of voriconazole depends on the dose and does not predict how fast the drug is cleared (voriconazole SmPC, EMA). Restart ivabradine only if the resting heart rate, based on repeated measurements, an ECG or 24-hour monitoring, is at least 70 beats per minute (ivabradine SmPC, EMA). Check potassium, magnesium and calcium before and during voriconazole treatment and correct them if needed (voriconazole SmPC, EMA, and label, FDA). If the two drugs have already been taken together, monitor the heart closely. Treat severe bradycardia with poor haemodynamic tolerance in a specialised setting with intravenous beta-stimulants such as isoprenaline and, if this is not enough, with temporary cardiac pacing (ivabradine SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3
- EMA: Ficha técnica: Ivabradina – Procoralan (EU/1/05/316), sección 4.3 (2025)– EMA, SmPC Procoralan (EU/1/05/316), texto en CIMA nº 05316003, información del producto actualizada 17/11/2025, secciones 4.3, 4.4 y 4.5
- FDA: Corlanor (ivabradine) prescribing information (2025)– FDA, DailyMed, Amgen, setid 92018a65-38f6-45f7-91d4-a34921b81d0d, v33, 11/2025, sections 2.1, 4, 5.3, 7.1 and 7.2
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5